Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 37 - Drugs for immunological or allergic disorders
Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141)
11/1999
11/02/1999US5976538 Adjuvant composition containing synthetic hydrophobic lipopolysaccharide
11/02/1999US5976533 Monoclonal antibodies reactive with defined regions of the T cell antigen receptor
11/02/1999CA2144055C Cloning and sequencing of allergens of dermatophagoides (house dust mite)
11/02/1999CA2053911C Recombinant antibody-toxin fusion protein
10/1999
10/28/1999WO1999054469A1 B-cell growth factor related protein
10/28/1999WO1999054456A1 ANTISENSE OLIGONUCLEOTIDES FOR THE INHIBITION OF INTEGRIN αv-SUBUNIT EXPRESSION
10/28/1999WO1999054440A1 CD19xCD3 SPECIFIC POLYPEPTIDES AND USES THEREOF
10/28/1999WO1999054351A1 Edg family gene, human h218
10/28/1999WO1999054349A2 Dermatophagoides nucleic acid molecules, proteins and uses thereof
10/28/1999WO1999054333A1 Pyrazolopyrimidinone cgmp pde5 inhibitors for the treatment of sexual dysfunction
10/28/1999WO1999054310A2 New substituted amides, their production and their use
10/28/1999WO1999054306A1 Isoquinolinesulfonamide derivatives and drugs containing the same as the active ingredient
10/28/1999WO1999054293A1 Substituted benzamides, their production and their use as cysteine protease inhibitors
10/28/1999WO1999054286A2 Btk inhibitors and methods for their identification and use
10/28/1999WO1999054284A1 Anthranilic acid derivatives as inhibitors of the cgmp-phosphodiesterase
10/28/1999WO1999053960A2 Enhancing immune responses to genetic immunization by using a chemokine
10/28/1999WO1999053954A1 Use of immunotoxins to induce immune tolerance to pancreatic islet transplantation
10/28/1999WO1999053947A1 Th2-MIGRATION PROMOTERS CONTAINING W/O EMULSIONS
10/28/1999WO1999053946A1 Modifications of antigens by the introduction of aldehyde groups and their use in enhancing the immune response
10/28/1999WO1999053944A1 Method for treating the endotoxic shock in mammals
10/28/1999WO1999053938A1 Isolated peptides corresponding to amino acid sequences of ny-eso-1, wherein bind to mhc class i and mhc class ii molecules, and uses thereof
10/28/1999WO1999053937A1 Immunopotentiators and antitumor agents
10/28/1999WO1999053935A1 Novel synergistic compositions containing aromatic compounds and terpenoids present in alpinia galanga
10/28/1999WO1999053920A1 Use of vitamin pp compounds
10/28/1999WO1999053912A1 Topical immunostimulation to induce langerhans cell migration
10/28/1999WO1999053899A1 Medicinal compositions for application to mucosa
10/28/1999WO1999053757A1 Autoantigenic fragments, methods and assays
10/28/1999WO1999039691A3 Pharmaceutical compositions
10/28/1999WO1999027080A3 Human protein kinase and kinase inhibitors
10/28/1999DE19818044A1 Reducing side effects or neutralizing action of carcinostatic or immunosuppressive agents, especially pyridine derivatives, using vitamin PP compounds, e.g. nicotinamide
10/28/1999CA2329495A1 Autoantigenic fragments, methods and assays
10/28/1999CA2329302A1 Modifications of antigens by the introduction of aldehyde groups and their use in enhancing the immune response
10/28/1999CA2328962A1 Btk inhibitors and methods for their identification and use
10/28/1999CA2328430A1 Substituted benzamides, their production and their use as cysteine protease inhibitors
10/28/1999CA2328413A1 Anthranilic acid derivatives as inhibitors of the cgmp-phosphodiesterase
10/28/1999CA2326685A1 Enhancing immune responses to genetic immunization by using a chemokine
10/28/1999CA2325848A1 B-cell growth factor related protein
10/28/1999CA2325821A1 Antisense oligonucleotides for the inhibition of integrin .alpha.v-subunit expression
10/28/1999CA2325391A1 Dermatophagoides nucleic acid molecules, proteins and uses thereof
10/28/1999CA2294980A1 Method for the treatment of endotoxic shock in mammels
10/27/1999EP0952218A2 Single chain, multiple antigen-binding molecule, its preparation and use
10/27/1999EP0951551A2 Ligand for receptor activator of nf-kappa b, ligand is member of tnf superfamily
10/27/1999EP0951550A1 Mammalian cytokine related to il10
10/27/1999EP0951542A2 Secreted proteins and polynucleotides encoding them
10/27/1999EP0951481A1 Use of substances with immunomodulating activity for the treatment of amyotrophic lateral sclerosis
10/27/1999EP0951474A1 Novel cyclosporin derivatives, method of preparation and pharmaceutical compositions containing them
10/27/1999EP0951469A1 Novel compounds
10/27/1999EP0951467A1 SUBSTITUTED NITROGEN CONTAINING HETEROCYCLES AS INHIBITORS OF p38 PROTEIN KINASE
10/27/1999EP0951295A1 Methods and compositions useful for inhibition of angiogenesis
10/27/1999EP0951289A1 $i(MYCOBACTERIUM VACCAE) FOR DOWN-REGULATION OF THE TH2 ACTIVITY OF THE IMMUNE SYSTEM
10/27/1999EP0539525B1 Vitaletheine and use in cell culture and therapy
10/27/1999CN1233254A Purine L-nucleosides, analogs and uses thereof
10/27/1999CN1233238A Acylaminoalkenylene-amide derivatives as NK1 and NK2 antagonists
10/27/1999CN1233187A HIVp-17 peptide fragment, compositions containing and methods for producing and using same
10/27/1999CN1233181A Method of treating ciliary dyskinesia with uridine triphosphates and related compounds
10/27/1999CN1233180A Treatment of the common cold or allergic rhinitis
10/27/1999CN1233179A Treatment of upper airway allergic responses with a combination of histamine receptor antagonists
10/27/1999CN1233171A Inhibition of nuclear transcription factor NF-'kappa' B by caffeic acid phenethyl ester (CAPE), derivatives of CAPE, capsaicin (8-methyl-N-vanillyl-6-nonenamide) and resiniferatoxin
10/27/1999CN1233150A Method for inhibiting the expression of FAS
10/27/1999CN1045884C High dose formulations containing active agent
10/26/1999US5973224 Dietetical combination preparations
10/26/1999US5973132 Expression of dna coding for house dust mite allergens.
10/26/1999US5973111 Novel compounds that are capable of binding to the active site of interleukin-1b-converting enzyme (ice) and inhibiting activity of that enzyme; administering to treat inflammatory, autoimmune, and neurodegenerative diseases
10/26/1999US5973009 Antioxidant and cytoprotecting activity
10/26/1999US5972972 Pyrazoles as human non-pancreatic secretory phospholipase A2 inhibitors
10/26/1999US5972946 Nervous system disorders; psychological disorders
10/26/1999US5972940 Arginine analogues having nitric oxide synthase inhibitor activity
10/26/1999US5972936 Benzofuran carboxamides and their therapeutic use
10/26/1999US5972917 Treatment and prophylaxis of hyperparathyroidism and hyperproliferative diseases, and in the modulation of the immune and inflammatory responses as well as the treatment of bone depletive disorders
10/26/1999US5972902 DNA encoding human IL-6 receptor antagonist and protein encoded thereby
10/26/1999US5972900 Conjugating target binding moiety consisting of an antibody or fragment which binds to secretory component of polymeric immunoglobulin receptor on surface of epithelium cell, nucleic acid binder, expression vector, compacting, administering
10/26/1999US5972688 HTm4 methods of treatment and assays, agonists and antagonists
10/26/1999US5972659 Introducing into e. coli a heterologous plasmid expression vector coding for the tobacco mosaic virus protein coat and a pathogen's epitope, separating fusion protein and lowering ph to form a self-aggregated protein and hapten for vaccines
10/26/1999US5972652 Polynucleotides encoding secreted proteins
10/26/1999US5972650 Can be used as vehicles for the delivery of nucleic acids that can serve as therapeutic agents and as part of vaccines designed to immunize people or animals against viral diseases.
10/26/1999US5972633 Antibodies against heart muscle actin
10/26/1999US5972352 Cloning of mite allergens
10/26/1999US5972349 Synthesis of polyribosylribitol phosphate oligosaccharides
10/26/1999US5972337 46 kilodalton human milk fat globule (HMFG) antigen, fragments and fusion protein
10/26/1999US5972336 Urease-based vaccine against helicobacter infection
10/26/1999CA2132993C Physiologically active substance
10/21/1999WO1999053099A1 Recombinant proteins of treponema pallidum and their use for a syphilis vaccine
10/21/1999WO1999053076A1 Tao protein kinases and methods of use therefor
10/21/1999WO1999053047A2 Porcine adenovirus type 3 genome
10/21/1999WO1999053038A2 Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins
10/21/1999WO1999053036A2 Ste20-related protein kinases
10/21/1999WO1999052935A1 Crystalline forms of 1s-[1alpha (2s*,3r*), 9alpha]-6, 10-dioxo-n- (2-ethoxy-5 -oxo-tetrahydro-3 -furanyl) -9-[[(1-isoquinolyl) carbonyl]-amino] octahydro-6h -piridazino[1, 2-a][1,2] diazepin- 1-carboxamide
10/21/1999WO1999052910A1 Bicyclic hydroxamic acid derivatives
10/21/1999WO1999052903A1 Prodrugs of benzofuranylmethyl carbamate nk1 antagonists
10/21/1999WO1999052898A1 N,n-disubstituted amides that inhibit the binding of integrins to their receptors
10/21/1999WO1999052889A1 (4-arylsulfonylamino)-tetrahydropyran-4-carboxylic acid hydroxamides
10/21/1999WO1999052862A1 Process for alkylating hindered sulfonamides useful in the production of matrix metalloproteinase inhibitors
10/21/1999WO1999052561A1 Inhibition of xenoreactive antibodies
10/21/1999WO1999052555A1 Methods and compositions using norastemizole in combination with leukotriene inhibitors
10/21/1999WO1999052554A1 Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors
10/21/1999WO1999052552A1 T cell inhibitory receptor compositions and uses thereof
10/21/1999WO1999052550A1 Polymer particle vaccine delivery system
10/21/1999WO1999052549A1 Adjuvant compositions
10/21/1999WO1999052548A2 Conjugate vaccines for the prevention of dental caries
10/21/1999WO1999052547A1 Vaccine compositions comprising cd-1 antigens and t-cell stimulating compound and methods of use thereof
1 ... 962 963 964 965 966 967 968 969 970 971 972 973 974 975 976 977 978 979 980 981 982 ... 1172